Navigation Links
eCardio Launches NEW Atrial Fibrillation Information System (AFIS(TM))
Date:5/15/2009

First Comprehensive Software Application to Offer Single Platform for AF Patient Management

BOSTON, May 15 /PRNewswire/ -- eCardio Diagnostics (www.ecardio.com) announced the launch of its NEW Atrial Fibrillation Information System (AFIS(TM)) today at Heart Rhythm 2009, the Annual Scientific Sessions of the Heart Rhythm Society. AFIS(TM) is an informatics solution that presents a longitudinal view of atrial fibrillation and tachyarrhythmic patients for teaching, research or clinical management. It is the first comprehensive software application to gather all associated clinical information in one place for AF patient management.

"Managing patients with atrial fibrillation is a daunting task, requiring the physician to evaluate numerous data sources, such as films, sonogram images and ECG reports," noted Nassir Marrouche, MD, Director of the Atrial Fibrillation Program at the University of Utah School of Medicine. "We developed AFIS(TM) to provide a single-platform application that not only gathers relevant clinical information in one place, but also provides a number of analytical tools to enable doctors to provide the best care for our patients."

Designed specifically to meet the needs of electrophysiologists in academic medicine, AFIS(TM) captures imaging, monitoring, procedural reports, clinic notes and patient history to provide clinicians with the most longitudinal data set on which to render treatment decisions. AFIS(TM) provides multi-factorial analysis tools for:

  • Data mining for clinical research;
  • Participation in the first international AF Registry;
  • Calculation of left atrial scar; and
  • Clinical management of the AF patient.

AFIS(TM) has been developed in collaboration with the University of Utah School of Medicine and is overseen by the Atrial Fibrillation Physician Advisory Board whose members include:

  • Nassir Marrouche, MD, Chair, Director of the Atrial Fibrillation Program, University of Utah School of Medicine
  • Oussama Wazni, MD, Electrophysiology Lab Director, Cleveland Clinic Foundation
  • Kalyanam Shivkumar, MD, PhD, Director of the Cardiac Arrhythmia Center, UCLA School of Medicine
  • Edward Gerstenfeld, MD, Cardiovascular Division, University of Pennsylvania School of Medicine
  • Professor Dr. Johannes Brachmann, MD, Chief of Cardiology, Med Klinik Klinikum Coburg
  • Nathan Segerson, MD, Kitsap Cardiology Consultants

AFIS(TM) will be installed at a select number of institutions in 2009 and will be available at additional centers next year.

About eCardio Diagnostics

eCardio Diagnostics, www.ecardio.com, is the nation's leading provider of comprehensive and advanced technologies, devices, services and solutions for the diagnosis, monitoring and subsequent clinical management of cardiac arrhythmias, predominantly in the ambulatory setting. eCardio provides leading-edge diagnostic innovations and solutions that optimize the flexibility, speed and accuracy of cardiac arrhythmia diagnoses--contributing to the timeliest, most effective and appropriate management of cardiac patients.


'/>"/>
SOURCE eCardio Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. eCardio Diagnostics Launches Academic Medicine Initiative
2. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
3. UPMC Health Plan Launches New Personal Health Record
4. HealthInsuranceFinders.com Launches Video Contest for Young Directors
5. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
6. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
7. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
8. Mannatech Launches Phase One of New Sales and Training Tools
9. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
10. Actavis Launches Carvedilol Tablets in the U.S.
11. MedQuist Re-launches New, Improved Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform the ... for lab operators and management to assess these processes with a critical eye—particularly ... unnecessary actions. , Created with the help of both internal and external ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... that over the last decade, student well-being has seriously declined. "When disenfranchised youth ... formal education, join the Islamic State to turn the historic multi-ethnic and multi-religious ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL COMPASS ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation of ... Chairman of the Board of Directors for CONTACT USA, and former member of the ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... DDS, PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on ... The Oral Reconstruction Foundation will present its annual Global Symposium at the Fontainebleau ...
(Date:4/24/2017)... WA (PRWEB) , ... April 24, 2017 , ... ... leading lifestyle brands, work wear distributors and International relief organizations across the globe ... The company also offers lifestyle and work wear collections via insectshield.com . ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: